Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term TRIAL. Found 28 abstracts

no pagination
Chang BL, Hughes L, Chen DY, Gross L, Ruth K, Giri VN. Validation of association of genetic variants at 10q with prostate-specific antigen (PSA) levels in men at high risk for prostate cancer. BJU international. 2014 May;113(5B):E150-E156.   PMCID: PMC 3830710
Kim SP, Karnes RJ, Nguyen PL, Ziegenfuss JY, Thompson RH, Han LC, Shah ND, Smaldone MC, Gross CP, Frank I, Weight CJ, Beebe TJ, Tilburt JC. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. BJU international. 2014 May;113(5B):E106-E111.
Marur S, Burtness B. Oropharyngeal squamous cell carcinoma treatment: current standards and future directions. Current Opinion in Oncology. 2014 May;26(3):252-8.   PMCID: No NIH funding
Cohen SJ, Punt CJ, Iannotti N, Saidman BH, Sabbath KD, Gabrail NY, Picus J, Morse MA, Mitchell E, Miller MC, Doyle GV, Tissing H, Terstappen L, Meropol NJ. Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer. Annals of Oncology. 2009 Jul;20(7):1223-9.   PMCID: Private funding
Demetri GD, Wang YF, Wehrle E, Racine A, Nikolova Z, Blanke CD, Joensuu H, von Mehren M. Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors. Journal of Clinical Oncology. 2009 Jul;27(19):3141-7.   PMCID: not NIH funded
Fang CY, Cherry C, Devarajan K, Li TY, Malick J, Daly MB. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecologic Oncology. 2009 Mar;112(3):594-600.   PMCID: PMC2697574
Kirkwood JM, Lee S, Moschos S, Albertini MR, Michalak JC, Sander C, Whiteside T, Butterfield LH, Weiner L. Immunogenicity and Antitumor Effects of Vaccination with Peptide Vaccine +/- Granulocyte-Monocyte Colony-Stimulating Factor and/or IFN-alpha 2b in Advanced Metastatic Melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clinical Cancer Research. 2009 Feb;15(4):1443-51.   PMCID: PMC2769898
Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter M, Seider M. RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH-RISK PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2009 Jun;74(2):383-7.   PMCID: PMC2905150
Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer. Journal of Clinical Oncology. 2009 Jan;27(1):100-5.   PMCID: PMC 2645095
Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. Journal of Clinical Oncology. 2008 Oct;26(29):4708-13.
Cohen SJ, Engstrom PF, Lewis NL, Langer CJ, McLaughlin S, Beard M, Weiner LM, Meropol NJ. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors. American Journal of Clinical Oncology-Cancer Clinical Trials. 2008 Feb;31(1):1-5.
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02. European Urology. 2008 Oct;54(4):816-24.
Hassett MJ, Hughes ME, Niland JC, Edge SB, Theriault RL, Wong YN, Wilson J, Carter WB, Blayney DW, Weeks JC. Chemotherapy Use for Hormone Receptor-Positive, Lymph Node-Negative Breast Cancer. Journal of Clinical Oncology. 2008 Dec;26(34):5553-60.
Marks DI, Perez WS, He W, Zhang MJ, Bishop MR, Bolwell BJ, Bredeson CN, Copelan EA, Gale RP, Gupta V, Hale GA, Isola LM, Jakubowski AA, Keating A, Klumpp TR, Lazarus HM, Liesveld JL, Maziarz RT, McCarthy PL, Sabloff M, Schiller G, Sierra J, Tallman MS, Waller EK, Wiernik PH, Weisdorf DJ. Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood. 2008 Jul;112(2):426-34.
Potter KL, Held-Warmkessel J. Intraperitoneal chemotherapy for women with ovarian cancer: Nursing care and considerations. Clinical journal of oncology nursing. 2008 Apr;12(2):265-71.
Rosenthal DI, Catalano PJ, Haller DG, Landry JC, Sigurdson ER, Spitz FR, Benson AB. Phase I study of preoperative radiation therapy with concurrent infusional 5-fluorouracil and oxaliplatin followed by surgery and postoperative 5-fluorouracil plus leucovorin for T3/T4 rectal adenocarcinoma: ECOG E1297. International Journal of Radiation Oncology Biology Physics. 2008 Sep;72(1):108-13.
Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin LL, DeWeese TL, Scardino PT, Stephenson AJ, Pollack A. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. Urology. 2008 Dec;72(6):1298-302.
Armstrong DK, Bookman MA, McGuire W, Bristow RE, Schilder JM. A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: A Gynecologic Oncology Group study. Gynecologic Oncology. 2007 Jun;105(3):667-71.
Bukowski RM, Ozols RF, Markman M. The management of recurrent ovarian cancer. Seminars in Oncology. 2007 Apr;34(2):S1-S15.
Fizazi K, Le Maitre A, Hudes G, Berry WR, Kelly WK, Eymord JC, Logothetis CJ, Pignon JP, Michiels S. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncology. 2007 Nov;8(11):994-1000.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term TRIAL

TRIAL CARCINOMA RADIOTHERAPY THERAPY IRRADIATION CARBOPLATIN FAILURE IMMEDIATE screening MORTALITY TUMORS oxaliplatin prostate-specific antigen PHASE-I ADJUVANT CHEMOTHERAPY IMPACT SURVIVAL GYNECOLOGIC-ONCOLOGY-GROUP PATTERNS FOLLOW-UP Prostate cancer STATISTICS RADICAL PROSTATECTOMY RISK CANCER Urology & Nephrology RANDOMIZED PHASE-II chemoradiation IMRT REFRACTORY OVARIAN COMPLETE RESPONSE DEPRIVATION HORMONE AGONISTS peritoneal cancer HIGHLIGHTS PRIMARY PERITONEAL SERVICES TASK-FORCE BRCA2 TUMOR-INFILTRATING LYMPHOCYTES RADICAL PREVENTION Radiation PLUS MEN GENOME-WIDE ASSOCIATION HIGH-RISK MELANOMA prostatic neoplasms NEOADJUVANT HIGH-DOSE INTERFERON-ALPHA-2B PHASE-III Eastern Cooperative Oncology Group DOCETAXEL phase I CHEMOTHERAPY ABDOMINAL HYSTERECTOMY DENDRITIC CELLS proteasome inhibitor MAIN METABOLITE CYTOLYTIC T-LYMPHOCYTES oncology guidelines CISPLATIN family history CLINICAL TARGET VOLUME COLORECTAL-CARCINOMA survey NEOPLASM TUBULIN CYCLOPHOSPHAMIDE Oncology TUMOR-REGRESSION metastatic TAMOXIFEN SOCIETY smoking MUTATIONS Ovarian cancer Pelvic lymph nodes COOPERATIVE-ONCOLOGY-GROUP radiation therapy PERIPHERAL-BLOOD prostate cancer RANDOMIZED-TRIAL FACTOR-KAPPA-B PROPHYLACTIC OOPHORECTOMY TOTAL MESORECTAL EXCISION PELVIC LYMPHADENECTOMY HUMAN-PAPILLOMAVIRUS SEQUENCES MESYLATE ADJUVANT IMMUNOTHERAPY BODY-COMPOSITION INHIBITION EARLY-STAGE capecitabine PERITONEAL CAPILLARIES STAGE-III OVARIAN POPULATION PHARMACOKINETICS RESPONSE RATES BIOCHEMICAL CONTROL PACLITAXEL CONSENSUS IRINOTECAN epithelial ovarian cancer colorectal cancer SURGICAL ADJUVANT BREAST PHARMACODYNAMIC END-POINTS head and neck squamous cell cancer FLUOROURACIL GUIDELINE WOMEN genetics SUSCEPTIBILITY Hormonal therapy EFFICACY SUPPRESSION LEUKEMIA GROUP-B PHOSPHATE GROUP Radiation therapy novel targets in LEUCOVORIN PHASE-II TRIAL PHARMACODYNAMICS HLA-A2 MELANOMAS CARCINOMATOSIS human papilloma virus COLORECTAL-CANCER ANTITUMOR-ACTIVITY BONE-MINERAL DENSITY Target volume UNITED-STATES STEM-CELL TRANSPLANTATION IDENTIFICATION Quality of life EXPRESSION paclitaxel ADENOCARCINOMA VITRO HOOSIER ONCOLOGY CHRONIC MYELOID-LEUKEMIA outcomes CELLS GROWTH-FACTOR VEGF NECK-CANCER CLINICAL-TRIALS rectal cancer SYMPTOMS EXTERNAL-BEAM RADIOTHERAPY LYMPHADENECTOMY
Last updated on Friday, August 14, 2020